SCIENTIFIC RESEARCH

Our pipeline

Overview

Our focus is developing highly-differentiated, first-in-class or best-in-class precision therapies against validated targets in oncology and other serious diseases.

Oncology

In Oncology, where precision medicine strategies have been utilized for the treatment of various solid and liquid tumors, we are developing PBI-200, a best-in-class, orally active TRK inhibitor. PBI-200 is a highly brain penetrant agent which overcomes the acquired clinical resistance mutations that are observed with current TRK inhibitor therapies. It is intended to treat a broad range of genomically-defined solid tumor cancers, including primary and metastatic brain cancers.

Dermatology

In Dermatology, we are developing a clinically-validated, first-in-class, selective TRK modulator, PBI-100, which contains anti-itch, anti-inflammatory and antiproliferative effects. We are developing PBI-100 for a range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis.

Oncology

PRECLINICAL
IND ENABLING
PHASE I
PHASE II

PBI-200 - NTRK Fusion Positive Solid Tumors

PBI-308 - Other Solid Tumors

Undisclosed

Dermatology

PRECLINICAL
IND ENABLING
PHASE I
PHASE II

PBI-100 - Psoriasis

PBI-100 - Atopic Dermatitis

For Clinical Trial Information, Please Visit the Links Below:

PBI-200: https://clinicaltrials.gov/ct2/show/NCT04901806

PBI-100: https://clinicaltrials.gov/ct2/show/NCT04882631

Learn More About Pyramid

Learn More